Correlation between fluoride release, surface hardness and diametral tensile strength of restorative glass ionomer cements.

Background: A complete and thorough understanding of head and neck anatomy by dental hygienists is fundamental for performing successful dental hygiene procedures in all clinical settings. Therefore, the aim of the present study was to assess the opinion of a population of dental hygiene students about the educational methods, their perceptions of the tooth drawing module, and their opinion about the content of Anatomy curriculum in an Italian University.

Material And Methods: A comprehensive survey about was developed and electronically distributed to the dental hygiene students.

The surgical management of triple mandibular fractures: A challenging task.

Background: The treatment of multiple mandibular fractures may often be challenging. The aim of this study was to evaluate the characteristics and outcomes of multiple mandibular fractures, with a focus on triple mandibular fractures.

Material And Methods: Patients with multiple (triple) mandibular fractures were included.

Short-Term Follow-up of Surgical Management Verruca Vulgaris with Modified Estlander Flap: A Case Report and Recent Literature Review.

Background: Verruca vulgaris (VV), widely known as warts, is a common benign skin lesion, which is caused by human papilloma virus. In some cases, VV can be developed within the oral cavity. Surgical excision is considered as the most preferred treatment modality for both cutaneous and oral VV which could be challenge to deal with.

Guselkumab: A new etiological factor of medication related osteonecrosis of the jaw (MRONJ)? A case report.

Medication Related Osteonecrosis of the Jaw (MRONJ) has traditionally been mostly attributed to the exposure to antiresorptive agents such as bisphosphonates and denosumab. Nevertheless, following the development of new medications in oncology, the spectrum of drugs associated with MRONJ widened, with, for example, tyrosine kinase inhibitors, mTOR inhibitor, or monoclonal antibodies against VEGF. To date, MRONJ has not been assessed or reported in patients treated with guselkumab so far.